4 – Alzheimers

When Eli Lilly stopped developing an Alzheimer’s compound a year ago due to side effects and lack of effectiveness, some experts expressed doubt about a similar drug being developed by Watertown-based EnVivo Pharmaceuticals . Those doubts may have intensified last week, when pharmaceutical giant Lilly released more data on the ... continue reading

Nearly a year ago, on these pages, 1 I expressed concerns regarding a draft report from workgroups at the Alzheimer’s Association International Conference on Alzheimer’s Disease (AAICAD) 2010, which suggested that the term “preclinical Alzheimer’s Disease” might be adopted.

Read more:
... continue reading